Response to “The use of ACMG secondary findings recommendations for general population screening: a policy statement of the American College of Medical Genetics and Genomics (ACMG)”

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    ACMG Board of Directors. The use of ACMG secondary findings recommendations for general population screening: a policy statement of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2019 Apr 25; https://doi.org/10.1038/s41436-019-0502-5 [Epub ahead of print].

  2. 2.

    Kalia SS, Adelman K, Bale SJ, et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. Genet Med. 2017;19:249–255.

  3. 3.

    American College of Medical Genetics and Genomics. Clarifications to ACMG’s recent statement on the use of ACMG secondary findings recommendations for general population screening: a policy statement of the American College of Medical Genetics and Genomics (ACMG). https://t.co/4omKKcgWTb. Accessed 1 May 2019.

  4. 4.

    Centers for Disease Control and Prevention. Tier 1 genomics applications and their importance to public health. https://www.cdc.gov/genomics/implementation/toolkit/tier1.htm. Accessed 30 April 2019.

Download references

Author information

Correspondence to Robert L. Nussbaum MD.

Ethics declarations

Disclosure

All authors are employees and stock holders in Invitae, a commercial genetic testing company that has pioneered the use of genetic testing of unaffected individuals seeking to know their risk for serious, unsuspected yet actionable oncological and cardiovascular disorders. In addition, RLN is a consultant for Pfizer Pharmaceuticals, and a consultant and stock holder in Maze Therapeutics and Genome Medical.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Further reading